
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Psychedelic use among psychiatric medication prescribers: Effects on well-being, depression, anxiety, and associations with patterns of use, reported harms, and transformative mental states
Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care.
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Our findings suggested that effect sizes for depression severity, as well as response and remission rates, were numerically greater for racemic ketamine than esketamine.
Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
This review will examine the preclinical and clinical evidence that psychoplastogens, such as ibogaine, ketamine, and classic psychedelics, may offer a unique, holistic alternative for the treatment of OUD.
A brief review on the potential of psychedelics for treating Alzheimer’s Disease and related depression
Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using microdosing, psychedelic drugs may prove to help combat this devastating disease by eliciting psychiatric benefits via acting through various mechanisms of action such as serotonin and dopamine pathways.
HOPE: A pilot study of psilocybin enhanced group psychotherapy in patients with cancer
This pilot study demonstrated the safety, feasibility, and possible efficacy of psilocybin-assisted group therapy for cancer patients dealing with depressive symptoms. Based on demonstrated efficacy and significant reductions in therapist time, future investigations with the group therapy model are warranted.
Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use
Hallucinogen dependence and abuse are DSM-IV diagnoses that are associated with significant morbidity, yet the specific hallucinogens that are most strongly linked to dependence and abuse are understudied.
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
There is some clinical evidence that chronic ingestion of full doses of MDMA is associated with VHD. We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies
We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin.
Addiction specialists' attitudes toward psychedelics: A National Survey
Participants overall expressed more positive attitudes to the therapeutic use of psychedelics than we had hypothesized. This may be attributable to the accelerating pace of psychedelics research in recent years. Given the strong influence of concern for addiction risk on attitudes, future study is warranted to explore the findings regarding these concerns.
Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review
All included studies suggest that psychedelics promise therapeutic value for eating disorders. These findings are preliminary, and randomised controlled trials are necessary to prove psychedelic-assisted psychotherapy efficacy and long-term implications for eating disorders.
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.
PHP psychedelics & music playlist retreat
This six-day, two-ceremony PHP retreat runs from Monday 18th to Saturday 23rd September in the Netherlands. We will use legal psilocybin truffles in the classic, tried & tested, lying listening to a carefully chosen music playlist format.
PHP psychedelics & meditation retreat
This six-day, two-ceremony PHP retreat runs from Monday 16th to Saturday 21st October in the Netherlands.
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Results suggest that psilocybin therapy is safe, tolerable and acceptable for female AN
The potential for psychedelics to improve coping skills and resilience in persons with newly diagnosed mild cognitive impairment or early Alzheimer’s disease
We discuss pre-clinical evidence suggesting that these benefits may also extend to Mild Cognitive Impairment and mild Alzheimer’s disease